How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In its second major partnership with a big pharma group, UK-based AI and multi-omics company Relation Therapeutics has agreed to seek out targets for allergic diseases on behalf of Novartis. The ...

Relation and Novartis collaborate to advance treatments for atopic diseases using AI and immuno-dermatology expertise. Relation receives $55 million upfront, with potential milestones up to $1.7 ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

The Question of Palestinian Statehood: A Conversation With Representative Ro Khanna Representative Ro Khanna discusses whether the United States should recognize Palestine as a sovereign state and the ...

The Consequences of Exporting Nvidia’s H200 Chips to China Three CFR experts discuss President Donald Trump’s decision to allow Nvidia to sell advanced AI chip sales to China and what implications it ...